Cubist Systematic Strategies LLC Takes $3.15 Million Position in Immunocore Holdings plc (NASDAQ:IMCR)

Cubist Systematic Strategies LLC bought a new stake in Immunocore Holdings plc (NASDAQ:IMCR) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 106,600 shares of the company’s stock, valued at approximately $3,145,000. Cubist Systematic Strategies LLC owned about 0.21% of Immunocore at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its stake in shares of Immunocore by 25.0% during the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after purchasing an additional 109,206 shares during the period. Hennion & Walsh Asset Management Inc. boosted its position in Immunocore by 125.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock valued at $1,463,000 after buying an additional 27,598 shares during the period. Crossmark Global Holdings Inc. boosted its position in Immunocore by 36.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company’s stock valued at $1,121,000 after buying an additional 10,217 shares during the period. Legal & General Group Plc grew its holdings in Immunocore by 17.3% in the 4th quarter. Legal & General Group Plc now owns 136,875 shares of the company’s stock worth $4,038,000 after acquiring an additional 20,163 shares during the last quarter. Finally, Primecap Management Co. CA increased its position in shares of Immunocore by 8.0% in the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company’s stock valued at $78,722,000 after acquiring an additional 196,530 shares during the period. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Bros. Advisors Lp Baker purchased 807,338 shares of Immunocore stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now directly owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.40% of the company’s stock.

Immunocore Trading Down 4.7 %

NASDAQ:IMCR opened at $28.40 on Friday. The firm has a market capitalization of $1.42 billion, a P/E ratio of -29.89 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a one year low of $23.15 and a one year high of $59.82. The company’s 50-day simple moving average is $28.81 and its 200 day simple moving average is $30.15.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.49) EPS. As a group, analysts forecast that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on IMCR shares. JPMorgan Chase & Co. cut their target price on Immunocore from $54.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, April 14th. Oppenheimer lifted their price objective on Immunocore from $85.00 to $86.00 and gave the stock an “outperform” rating in a research report on Thursday. Mizuho reduced their target price on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a research note on Monday, April 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 price target on shares of Immunocore in a research note on Thursday, April 10th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and an average target price of $58.13.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.